Elemento Lab

Publications

Found 506 results
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z et al..  2018.  Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.. Mol Cell. 70(3):531-544.e9.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Rendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE.  2022.  Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.. medRxiv.
Park K, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T, Borczuk A, Mosquera JMiguel, Pan Q, Sboner A et al..  2020.  Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med.
K Devi SP, Wang E, Jaiswal A, Konieczny P, Kim T-G, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN et al..  2025.  PD-1 is requisite for skin T cell formation and specification by TGFβ.. Nat Immunol. 26(8):1339-1351.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. 6(4):102029.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al..  2012.  A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.. Clin Cancer Res. 18(7):2032-8.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Elemento O, Bulusu KC.  2024.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. bioRxiv.
Xu C, Us I, Cohen-Setton J, Milo M, Sidders B, Fitzgibbon J, Melnick AM, Pan H, Bulusu KC, Elemento O.  2026.  PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.. Res Sq.
Cheng APellan, Rusinek I, Sossin A, Widman AJ, Meiri E, Krieger G, Hirschberg O, Tov DShem, Gilad S, Jaimovich A et al..  2025.  Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules.. bioRxiv.
O
Hanif SZ, Au CMCherie, Torregroza I, Kutz C, Jannath SY, Fabiha T, Bhinder B, Washburn MP, Devost D, Liu S et al..  2025.  The Orphan G Protein-Coupled Receptor GPR52 is a Novel Regulator of Breast Cancer Multicellular Organization.. bioRxiv.
Sivakumar R, Chan M, Shin JStella, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS.  2019.  Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.. Oncoimmunology. 8(12):e1670019.
Kudman S, Semaan A, Assaad MAl, Gogineni S, M Martin L, Mathew S, Elemento O, Wilkes DC, Mosquera JMiguel.  2024.  Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine.. Curr Protoc. 4(6):e1093.
Kyei I, Bea VJ, Gyan KK, Adjei E, Stonaker B, Bekele M, Abebe E, Davis M, Boakye A, Boateng R et al..  2025.  Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).. Ann Surg Oncol.
Elemento O, Rubin MA, Rickman DS.  2012.  Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer.. Cell Cycle. 11(18):3380-3.
Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Rickman DS, T Soong D, Moss B, Mosquera JMiguel, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V et al..  2012.  Oncogene-mediated alterations in chromatin conformation.. Proc Natl Acad Sci U S A. 109(23):9083-8.
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.
Seo BRi, Bhardwaj P, Choi S, Gonzalez J, Eguiluz RCAndresen, Wang K, Mohanan S, Morris PG, Du B, Zhou XK et al..  2015.  Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis.. Sci Transl Med. 7(301):301ra130.